Eprosartan
When ATH:
C09CA02
Characteristic.
White or off-white free-flowing crystalline powder. Insoluble in water, is highly soluble in ethanol.
Pharmacological action.
Antigipertenzivnoe.
Application.
Arterial hypertension.
Contraindications.
Hypersensitivity, pregnancy, lactation.
Restrictions apply.
Childhood (safety and effectiveness in children have not identified).
Pregnancy and breast-feeding.
Contraindicated in pregnancy. At the time of treatment should stop breastfeeding.
Side effects.
Headache, dizziness, weakness, diarrhea, rhinitis, rarely zagrudinnaya pain, breathlessness, cough, angioedema.
Cooperation.
Compatible with calcium channel blockers, thiazide diuretics (summation effects), lipid-lowering drugs.
Overdose.
Symptoms: hypotension.
Treatment: simptomaticheskaya therapy.
Dosing and Administration.
Inside, regardless of the meal, 600-800 mg 1 once a day (morning) 2-3 weeks. The maximum daily dose - 1200 mg.
Precautions.
To use caution in stenosis of the aortic or mitral valve, hypertrophic cardiomyopathy, CHD, severe heart failure, Bilateral renal artery stenosis or renal artery stenosis sole kidney, renal failure (Cl creatinine less than 30 ml / min), hyperkalemia. Not recommended for patients with primary hyperaldosteronism.
Cooperation
| Active substance | Description of interaction |
| Warfarin | Do not change (mutually) effect; permitted the simultaneous use. |
| Verapamil | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Gidroxlorotiazid | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Glibenclamide | Against the background does not change the effect of eprosartan. |
| Indapamid | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Lithium carbonate | FMR. Maybe unpredictable change (mutually) effect; with a joint appointment is necessary to monitor the level of lithium in the serum. |
| Methyldopa | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Nimodipine | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Nitroglycerin | FMR: synergism. Enhances the hypotensive effect. |
| Pentoxifylline | FMR: synergism. Strengthens (insignificantly) hypotensive effect. |
| Risperidone | FMR: synergism. Enhances the hypotensive effect. |
| Terazosin | FMR: synergism. Significantly increases (mutually) hypotensive effect; the combined appointment may require dose reduction. |
